Nov 30, 2007 by Brian LawlerFDA Throws Adolor a BoneThe pharmaceutical gets an advisory panel hearing on its lead drug.
Nov 30, 2007 by Brian LawlerMGI's Turn for "Strategic Alternatives"MGI Pharma whispers those magic words.
Nov 29, 2007 by Brian LawlerAnother Chapter in Glaxo's Relenza SagaThe FDA votes to revise the label for a flu vaccine drug.
Nov 28, 2007 by Brian LawlerWelcome to the New Era of FDA RegulationFDA approvals are not keeping pace with drugmakers' push to get new compounds on the market.
Nov 27, 2007 by Brian LawlerInterMune Bets on the FutureInterMune trades a future royalty expense for cash.
Nov 27, 2007 by Brian LawlerCardiome Makes Them WaitThe release of data on an oral version of its lead heart drug is delayed.
Nov 26, 2007 by Brian LawlerGlaxo Goes Holiday ShoppingThe pharmaceutical snaps up another acquisition.
Nov 23, 2007 by Brian LawlerA Bird in the Hand for ExelixisExelixis raises cash by selling expensive mice.
Nov 21, 2007 by Brian LawlerPfizer Finds an Old FriendThe drugmaker makes a partner its newest acquisition.
Nov 21, 2007 by Brian LawlerElan and Biogen DeniedElan's lead drug is denied a label expansion in Europe.
Nov 21, 2007 by Brian LawlerCV Therapeutics Tries to Cast a Wider NetIt submits multiple marketing applications for Ranexa, its lead drug.
Nov 16, 2007 by Brian LawlerScrutinizing FDA Drug ApprovalsThe pace has certainly slowed since the Vioxx recall.
Nov 16, 2007 by Brian LawlerWaiting on a Friend for DendreonIt looks for a marketing partner for a prostate cancer drug that's in clinical trials.
Nov 15, 2007 by Brian LawlerFlamel Now Part of Wacky Lawsuit HijinksShareholders try to sue the inflammable pants off Flamel.
Nov 14, 2007 by Brian LawlerIs the FDA Still Approving New Drugs?A closer look at FDA drug approvals.
